1 nes recommend that testing for serum markers
be repeated every 12-24 weeks during antiviral therapy a
2 V-RNA titer were monitored, and liver biopsy
was repeated every 12 months.
3 Treatment
was repeated every 14 days for seven cycles: Bevacizumab
4 Each course
was repeated every 14 days for six planned courses.
5 Cycles
were repeated every 14 days until completion of RT.
6 Treatment cycles
were repeated every 14 days; one course of therapy inclu
7 For the participants in the IMAS, visits
are repeated every 18 months after the baseline visit (4
8 , timed tracheal aspiration lasted 0.3 secs,
was repeated every 2 mins, and was synchronized with the
9 n decline was less than 4 mo, but if therapy
was repeated every 2 mo patients experienced additive an
10 Treatment
was repeated every 2 weeks if the absolute neutrophil co
11 Tumor assessments
were repeated every 2 cycles.
12 d at the time of tantalum clip insertion and
were repeated every 2 months during 6 months, and every
13 Cycles
were repeated every 2 to 6 weeks.
14 Each regimen
was repeated every 21 days and each included cisplatin (
15 Treatment
was repeated every 21 days for six cycles or until disea
16 Treatment
was repeated every 21 days, and one complete course of t
17 This treatment
was repeated every 21 days.
18 Treatment
was repeated every 21 days.
19 A course
was repeated every 21 days.
20 Cycles
were repeated every 21 days for a maximum of six courses
21 Cycles
were repeated every 21 days for a total of three cycles.
22 Cycles
were repeated every 21 days for eight cycles.
23 Treatment cycles
were repeated every 21 days until disease progression or
24 Cycles
were repeated every 21 days until disease progression, t
25 Cycles
were repeated every 21 days until progression or a maxim
26 Cycles
were repeated every 21 days up to eight cycles.
27 Cycles
were repeated every 21 days.
28 2) and cisplatin 75 mg/m(2) on day 1; cycles
were repeated every 21 days.
29 000 mg/m(2) IV on days 1, 8, and 15; courses
were repeated every 21 days.
30 Cycles
were repeated every 21 days; all patients were supplemen
31 Cycles
were repeated every 21 to 28 days.
32 Cycles
were repeated every 22 days.
33 Treatment
was repeated every 28 days for a total of six cycles.
34 udarabine plus rituximab (FR) administration
was repeated every 28 days for six cycles.
35 Treatment
was repeated every 28 days until maximum response or a m
36 Treatment cycles
were repeated every 28 days following the first daily do
37 These cycles
were repeated every 28 days for a maximum of six cycles.
38 Cycles
were repeated every 28 days.
39 Courses
were repeated every 28 days.
40 Treatment cycles
were repeated every 28 to 35 days.
41 inutes, during which riboflavin instillation
was repeated every 3 minutes.
42 Treatment
was repeated every 3 weeks if the ANC was > or = 2,000/m
43 Treatment
was repeated every 3 weeks.
44 Measurements
were repeated every 3 mo for 1 y.
45 Cycles
were repeated every 3 weeks for a maximum of four cycles
46 inistered on day 1 of each cycle, and cycles
were repeated every 3 weeks for six treatments.
47 Cycles
were repeated every 3 weeks for up to six cycles.
48 Cycles
were repeated every 3 weeks to a maximum of eight cycles
49 Both regimens
were repeated every 3 weeks to a maximum of seven cycles
50 Cycles
were repeated every 3 weeks until progression or a minim
51 Cycles
were repeated every 3 weeks until progression or a total
52 Treatment cycles
were repeated every 3 weeks.
53 Cycles
were repeated every 3 weeks.
54 Treatments
were repeated every 3 weeks.
55 Courses
were repeated every 3 weeks.
56 Imaging
was repeated every 30 minutes up to 4 hours.
57 old and hunger scores, and plasma parameters
were repeated every 30 min during a 150-min period.
58 The injection
was repeated every 4 weeks until the regression of seeds
59 Chemotherapy
was repeated every 4 weeks.
60 with 17beta-estradiol (10 mug, s.c.), which
was repeated every 4-5 days.
61 ted underwent a baseline OCT and OCTA, which
were repeated every 4 to 6 months.
62 Courses
were repeated every 4 to 8 weeks.
63 Complete patient evaluations
were repeated every 4 weeks.
64 Courses
were repeated every 4 weeks.
65 Cycles
were repeated every 4 weeks.
66 ollected in a 2.5-s period, and this process
is repeated every 5 s.
67 after 6 to 9 days of rest, and courses could
be repeated every 6 to 12 weeks in stable or responding
68 Grading and chlamydial detection
were repeated every 6 months for 3 years.
69 le (one cycle), and suramin treatment cycles
were repeated every 6 months for a total of four cycles.
70 Dossenheim, Germany), and visual field tests
were repeated every 6 months.
71 Treatment cycles
were repeated every 6 weeks in responding or stable pati
72 Cycles
were repeated every 6 weeks.
73 These treatments
were repeated every alternate day for 2 weeks, for a tot
74 l cis-trans isomerization in prolines, which
are repeated every fifth residue in the main chain of EL
75 ertion as well as occasional slow steps that
are repeated every &
gt;410 bp.
76 nal connectivity; thus, treatment with CM101
was repeated every other day for five more infusions for